Abstract |
Imatinib and recombinant interferon alpha (rIFNalpha) can induce remission in polycythemia vera (PV) patients, but gauging the depth of responses has not been possible due to lack of a specific disease marker. We found that patients undergoing imatinib (n = 14) or rIFNalpha (n = 7) therapy remained strongly positive for V617F JAK2, although there was a significant reduction in the median percentage of mutant alleles that correlated with hematologic response (P = .001). Furthermore, individuals who achieved complete hematologic remission had lower levels of V617F than those who did not (P = .001). Of 9 imatinib-treated cases for whom pretreatment samples were available, 7 with no or partial hematologic responses showed a marginal increase (median, 1.2-fold; range, 1.0-1.5) in the percentage of V617F alleles on treatment, whereas the 2 patients who achieved complete hematologic remission showed a 2- to 3-fold reduction. Our data indicate that, although PV patients may benefit from imatinib or rIFNalpha, molecular responses are relatively modest.
|
Authors | Amy V Jones, Richard T Silver, Katherine Waghorn, Claire Curtis, Sebastian Kreil, Katerina Zoi, Andreas Hochhaus, David Oscier, Georgia Metzgeroth, Eva Lengfelder, Andreas Reiter, Andrew J Chase, Nicholas C P Cross |
Journal | Blood
(Blood)
Vol. 107
Issue 8
Pg. 3339-41
(Apr 15 2006)
ISSN: 0006-4971 [Print] United States |
PMID | 16352805
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Benzamides
- Biomarkers
- Interferon Type I
- Piperazines
- Protein Kinase Inhibitors
- Proto-Oncogene Proteins
- Pyrimidines
- Recombinant Proteins
- Imatinib Mesylate
- Protein-Tyrosine Kinases
- JAK2 protein, human
- Janus Kinase 2
|
Topics |
- Adult
- Aged
- Alleles
- Amino Acid Substitution
- Antineoplastic Agents
(administration & dosage)
- Benzamides
- Biomarkers
(blood)
- Dose-Response Relationship, Drug
- Female
- Hematopoiesis
(drug effects, genetics)
- Humans
- Imatinib Mesylate
- Interferon Type I
(administration & dosage)
- Janus Kinase 2
- Male
- Middle Aged
- Piperazines
(administration & dosage)
- Polycythemia Vera
(blood, drug therapy, genetics)
- Protein Kinase Inhibitors
(administration & dosage)
- Protein-Tyrosine Kinases
(antagonists & inhibitors, genetics)
- Proto-Oncogene Proteins
(antagonists & inhibitors, genetics)
- Pyrimidines
(administration & dosage)
- Recombinant Proteins
- Remission Induction
(methods)
|